{
  "pmcid": "5265688",
  "sha256": "fb34a1ce6ef286f301addc2bb52a4c2ef48c5d225d411d793e850cdeb2b999e9",
  "timestamp_utc": "2025-11-09T23:57:10.709553+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 8.48429487179487,
    "reading_ease": 51.60028846153847,
    "word_count": 234
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Everolimus Plus Reduced-Dose Tacrolimus in Liver Transplant Recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Adult recipients of primary liver transplants from deceased donors, with an eGFR of 30 mL/min per 1.73 m² or greater, were randomised 1:1:1"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adult recipients of primary liver transplants from deceased donors, with an eGFR of 30 mL/min per 1.73 m² or greater"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1:1 to EVR + rTAC, TAC-WD, or TAC-C"
      },
      "Objective": {
        "score": 1,
        "evidence": "This international, randomised controlled trial assessed the impact of everolimus plus reduced-dose tacrolimus (EVR + rTAC) on renal function and efficacy compared to standard-dose tacrolimus (TAC-C)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the composite of treated biopsy-proven acute rejection, graft loss, or death at 12 months"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was stratified by pretransplant HCV status and eGFR"
      },
      "Blinding": {
        "score": 1,
        "evidence": "The study was open-label"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 719 participants, 211 were from North America"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The study was open-label, and the analysis was intention-to-treat"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "At month 12, the composite efficacy endpoint was 10.9% for EVR + rTAC and 13.1% for TAC-C. Mean changes in eGFR favored EVR + rTAC at months 12 (+3.7 vs −4.5 mL/min per 1.73 m²; P = 0.032) and 24 (+2.7 vs −6.6 mL/min per 1.73 m²; P = 0.042)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the EVR + rTAC group, leading to higher discontinuation rates. Common adverse events included hypertension, leukopenia, and hyperlipidemia"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01204993"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Novartis Pharmaceuticals"
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}